Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Enanta Pharmaceuticals Company Profile (NASDAQ:ENTA)

Consensus Ratings for Enanta Pharmaceuticals (NASDAQ:ENTA) (?)
Ratings Breakdown: 2 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $43.20 (11.51% upside)

Analysts' Ratings History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Show:
DateFirmActionRatingPrice TargetDetailsShare
7/7/2014JMP SecuritiesDowngradeOutperform -> Market PerformViewTweet This Rating  Share This Rating on StockTwits
6/24/2014Robert W. BairdDowngradeOutperform -> Neutral$41.00ViewTweet This Rating  Share This Rating on StockTwits
4/16/2014ZacksUpgradeNeutral -> Outperform$43.80ViewTweet This Rating  Share This Rating on StockTwits
3/10/2014Leerink SwannBoost Price Target$29.00 -> $45.00ViewTweet This Rating  Share This Rating on StockTwits
2/18/2014JMP SecuritiesBoost Price TargetOutperform$50.00ViewTweet This Rating  Share This Rating on StockTwits
2/10/2014Credit SuisseBoost Price Target$36.00 -> $43.00ViewTweet This Rating  Share This Rating on StockTwits
1/27/2014Robert W. BairdInitiated CoverageOutperform$41.00ViewTweet This Rating  Share This Rating on StockTwits
1/1/2014ZacksDowngradeOutperform -> Neutral$33.30ViewTweet This Rating  Share This Rating on StockTwits
11/29/2013ZacksUpgradeNeutral -> Outperform$29.00ViewTweet This Rating  Share This Rating on StockTwits
10/2/2013ZacksUpgradeNeutral -> Outperform$25.40ViewTweet This Rating  Share This Rating on StockTwits
4/15/2013JPMorgan Chase & Co.Initiated CoverageOverweightViewTweet This Rating  Share This Rating on StockTwits
4/15/2013JMP SecuritiesInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
4/15/2013Leerink SwannInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
4/15/2013Credit SuisseInitiated CoverageOutperform$29.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2012 forward)